Organization
Basser Center for BRCA
5 abstracts
Abstract
Breast cancer risk associated with missense variants in BRCA2.Org: Ambry Genetics, Harvard T.H. Chan School of Public Health, Sierra Madre, Abramson Cancer Center, University of Pennsylvania,
Abstract
Polygenic risk score calibration and association with breast cancer in diverse ancestries.Org: Myriad Genetics, Inc., Vanderbilt University Medical Center, Abramson Cancer Center, University of Pennsylvania, Providence Health/St John Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).Org: University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA, University of Pennsylvania, Hospital of the University of Pennsylvania, Univ of Pa,
Abstract
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.Org: University of Pennsylvania, Dana-Farber Cancer Institute, University of Kansas Cancer Center, Kansas City, KS, Memorial Sloan Kettering Cancer Center, Winship Cancer Center of Emory University,
Abstract
Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.Org: University of Pennsylvania, Basser Center for BRCA, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic,